Support line (toll-free) (844) 835-4325 | Events help (608) 828-8852 | Community

Free To Breathe - A Partnership For Lung Cancer Survival

participant Login

News

Featured Clinical Trial of the Week: A New Targeted Therapy for NSCLC Patients with an ALK Mutation

  • August 02 2013

    Share |
    Featured Clinical Trial of the Week: A New Targeted Therapy for NSCLC Patients with an ALK Mutation

    A mutation in the ALK gene is present in approximately 3%-5% of all non-small cell lung cancer cases. ALK inhibitors, such as crizotinib, work by targeting the ALK gene and preventing it from working with other molecules to drive cancer growth. In this clinical trial, researchers will test the effectiveness of an experimental ALK inhibitor called LDK378.

    Eligibility
    Patients with stage IIIB or stage IV NSCLC and a mutation in the ALK gene. Patients who have received previous treatment with crizotinib or another ALK inhibitor are not eligible, but may enroll in this clinical trial testing the same therapy.

    Visit ClinicalTrials.gov for more information on this trial.

    If you’re looking for further information on this and/or other lung cancer clinical trials, please contact our Clinical Trials Matching Service, where trained representatives will match your particular cancer and health issues to clinical trials that are available for you.

    0 comments

Leave a comment

Comment Guidelines

Basic HTML formatting permitted -
<ul>, <li>, <strong>, <em>, <a href>, <blockquote>, <code>

©2017 Free To Breathe | Lung Cancer Research Foundation | Federal Tax ID #14-1935776 | LCRF is a 501(c)(3) public charity.